We believe this site might serve you best::

United States

United States

Choose language: English

Promega's Cookie Policy

Our website uses functional cookies that do not collect any personal information or track your browsing activity. When you select your country, you agree that we can place these functional cookies on your device.

P450-Glo™ CYP1A2 Assay and Screening Systems

V9920

A Luminescent Assay and Screening System for Measuring CYP1A2 Activity

  • Screening system includes a complete set of reagents
  • Luminescent format eliminates need for time-consuming analyses
  • Broad dynamic range and low background

Choose a product

Size

Catalog number selected: V8771

$ 140.00 Your price: Log In

Add to Helix Add to Helix
P450-Glo™ CYP1A2 Assay and Screening Systems
Assay System/10ml
$ 140.00
Your price: Log In
Change Configuration

P450-Glo™ CYP1A2 Assay and Screening Systems

The P450-Glo™ CYP1A2 Assay provides a homogeneous, luminescent method for measuring cytochrome P450 CYP1A2 activity. The assay employs luminogenic P450 substrates that are derivatives of beetle luciferin, a substrate for luciferase enzymes. The derivatives are not substrates for luciferase but are converted by P450s to luciferin, which in turn reacts with luciferase to produce light that is directly proportional to the activity of the P450. 

This luminescent assay exhibits exquisite sensitivity, low background signals and broad dynamic range. It generates a "glow-type" luminescent signal, produced using derivatized luciferins as P450 substrates and a recombinant stabilized luciferase (Ultra-Glo Luciferase) coupled with a proprietary buffer system. The half-life of the luminescent output is greater than two hours, eliminating the need for luminometers with injectors and allowing batch plate processing. The luminescent format also eliminates the need for time-consuming analyses such as HPLC.

The luciferin-based substrates are readily taken up by cells and rapidly converted into luciferin inside the cell, which reduces the incubation time required (typically 30-60 minutes). Other benefits of the P450-Glo™ CYP2B6 Assay include a formulation that minimizes the incidence of false positives due to inhibition of luciferase by analytes when screening for cytochrome P450 inhibitors. Z´ values greater than 0.8 are achieved in either 96- or 384-well plate formats and confer highly predictive results.

 Assays are complete systems that include a membrane preparation containing recombinant human cytochrome P450 enzyme, a luminogenic cytochrome P450 substrate appropriate for the enzyme, an NADPH regeneration system, reaction buffer, Luciferin Detection Reagent and Luciferin-Free Water.

The P450-Glo™ CYP1A2 Induction/Inhibition Assay contains a new substrate for cytochrome 1A2 that is very well suited for all applications involving human CYP1A2 and is the best substrate available for cell-based applications. The substrate, Luciferin-1A2, is readily taken up by cells and converted into a luciferin precursor by CYP1A2. The luciferin precursor is rapidly converted into luciferin following the addition of  D-cysteine. After addition of luciferin-1A2 to cells, the assay can be completed in approximately one hour. The low background and high signal-to-noise ratio produced using luciferin-1A2 means less starting material is required.

The P450-Glo™ CYP1A2 Screening System

The P450-Glo™ CYP1A2 Screening System provides a complete set of reagents for performing luminescent cytochrome P450 assays. The system includes a membrane preparation containing recombinant human cytochrome P450 enzyme, a luminogenic cytochrome P450 substrate appropriate for the enzyme, an NADPH Regeneration System, reaction buffer, Luciferin Detection Reagent and Luciferin-Free Water. The membranes are prepared from baculovirus-infected insect cells and contain human cytochrome P450, P450 reductase, and cytochrome b5. The P450-Glo™ Screening System also contains a membrane fraction devoid of cytochrome P450 activity as a negative control. The assays are ideal for testing the effects of drugs and new chemical entities on cytochrome P450 enzyme activities. 

Protocols

Specifications

You are viewing: 10ml Change Configuration

What's in the box?

Item Part # Size

Luciferin Detection Reagent

V859A 1 x 1 each

Luciferin-ME, 5mM

V862A 1 x 200μl

Reconstitution Buffer

V865A 1 x 10ml

SDS

Choose language:

Certificate of Analysis

Search for Specific Certificate:

View more results
No results
Loading…

Use Restrictions

For Research Use Only. Not for Use in Diagnostic Procedures.

Storage Conditions

BB

Patents and Disclaimers

U.S. Pat. Nos. 6,602,677, 7,241,584, 8,030,017 and 8,822,170 and other patents and patents pending.

U.S. Pat. Nos. 7,692,022 and 8,106,052 and other patents pending.

Specifications

You are viewing: 50ml Change Configuration

What's in the box?

Item Part # Size

Luciferin Detection Reagent

V859B 1 x 1 each

Luciferin-ME, 5mM

V862B 1 x 1ml

Reconstitution Buffer

V865B 1 x 50ml

SDS

Choose language:

Certificate of Analysis

Search for Specific Certificate:

View more results
No results
Loading…

Use Restrictions

For Research Use Only. Not for Use in Diagnostic Procedures.

Storage Conditions

BB

Patents and Disclaimers

U.S. Pat. Nos. 6,602,677, 7,241,584, 8,030,017 and 8,822,170 and other patents and patents pending.

U.S. Pat. Nos. 7,692,022 and 8,106,052 and other patents pending.

Specifications

You are viewing: 10ml Change Configuration

What's in the box?

Item Part # Size

Luciferin-1A2

V841A 1 x 30μl

D-Cysteine, 500X

V843A 1 x 100μl

Luciferin Detection Reagent

V859A 1 x 1 each

Reconstitution Buffer

V865A 1 x 10ml

SDS

Choose language:

Certificate of Analysis

Search for Specific Certificate:

View more results
No results
Loading…

Use Restrictions

For Research Use Only. Not for Use in Diagnostic Procedures.

Storage Conditions

BB

Patents and Disclaimers

U.S. Pat. Nos. 6,602,677, 7,241,584, 8,030,017 and 8,822,170 and other patents and patents pending.

U.S. Pat. No. 8,592,172 and other patents pending.

U.S. Pat. No. 8,551,721 and other patents pending.

Specifications

You are viewing: 50ml Change Configuration

What's in the box?

Item Part # Size

Luciferin-1A2

V841A 2 x 30μl

D-Cysteine, 500X

V843A 1 x 100μl

Luciferin Detection Reagent

V859B 1 x 1 each

Reconstitution Buffer

V865B 1 x 50ml

SDS

Choose language:

Certificate of Analysis

Search for Specific Certificate:

View more results
No results
Loading…

Use Restrictions

For Research Use Only. Not for Use in Diagnostic Procedures.

Storage Conditions

BB

Patents and Disclaimers

U.S. Pat. Nos. 6,602,677, 7,241,584, 8,030,017 and 8,822,170 and other patents and patents pending.

U.S. Pat. No. 8,592,172 and other patents pending.

U.S. Pat. No. 8,551,721 and other patents pending.

Specifications

You are viewing: 1,000 assays Change Configuration

What's in the box?

Item Part # SizeConcentration

Luciferin-Free Water

V348A 1 x 50ml

Potassium Phosphate Buffer, 1M

V446A 1 x 5ml

Control Membranes

V476A 1 x 100μl5mg/ml

CYP1A2 (1pmol/μl) + Reductase

V477A 1 x 500μl

Luciferin Detection Reagent

V859B 1 x 1 each

Luciferin-ME, 5mM

V862B 1 x 1ml

Reconstitution Buffer

V865B 1 x 50ml

Solution A—NADPH Regeneration System

V952A 1 x 2.75ml

Solution B—NADPH Regeneration System

V953A 1 x 600μl

SDS

Choose language:

Certificate of Analysis

Search for Specific Certificate:

View more results
No results
Loading…

Use Restrictions

For Research Use Only. Not for Use in Diagnostic Procedures.

Storage Conditions

Patents and Disclaimers

U.S. Pat. Nos. 6,602,677, 7,241,584, 8,030,017 and 8,822,170 and other patents and patents pending.

U.S. Pat. No. 8,592,172 and other patents pending.

U.S. Pat. No. 8,551,721 and other patents pending.

Resources

workflow-background

Small Molecule Drug Discovery Workflow

Choose your country

Americas

Brazil
Brazil
Canada
Canada
United States
United States

Pacific Asia

Australia
Australia
India
India
Japan
Japan
Korea, Republic of
Korea, Republic of
Singapore
Singapore

Europe

Austria
Austria
Belgium
Belgium
Denmark
Denmark
Estonia
Estonia
Finland
Finland
France
France
Germany
Germany
Iceland
Iceland
Italy
Italy
Luxembourg
Luxembourg
Netherlands
Netherlands
Norway
Norway
Poland
Poland
Spain
Spain
Sweden
Sweden
Switzerland
Switzerland
United Kingdom
United Kingdom